Escobedo-de la Cruz RC, Suárez-Cuenca JA, Huerta-Ramírez S, Rodríguez-López L, Muñoz-Campos NM, Gallegos-Hernández O

Language: Spanish
References: 17
Page: 536-541
PDF size: 468.87 Kb.

ABSTRACT

Background: There is a pro-atherogenic trend in patients with chronic liver disease (CLD). The carotid intima media thickness (CIMT) by Doppler is useful for early diagnosis of subclinical atherogenesis, which correlates with cardiovascular risk factors. This study assessed the relation between subclinical atherogenesis and ankle to brachial index (ABI) in patients with CLD.
Material and methods: CLD patients attending to Internal Medicine, General Hospital of Xoco from March 2014 to February 2015 were included. ABI and CIMT were measured by conventional methods. The sample was divided into two groups according to the determination of CIMT (CIMT ≤0.05cm and CIMT ›0.05cm). The results were compared using mean difference, risk analysis (odds ratio), and standardization for variables of potential interaction (logistic regression).
Results: Sixty patients, 53 (88.3%) males and 7 (11.6%) females, mean age 47 years-old were recruited. The ABI mean was 1.012 ± 0.144 in the group of CIMT ›0.05. The ABI ‹0.9 was associated with CIMT risk OR = 12.42; 95% CI 1.46 - 105.7, p = 0.012. This association was modified when variables of potential interaction were added to the logistic regression, mainly uric acid (›5.2mg/dl) OR 5.3 (95% CI, 1.28-22.09), VSG (›20sec) OR 6.9 (95% CI, 1.68-28.9), age ›50 years-old OR 7.1 (95% CI, 1.10-47.03).
Conclusions: We found that ABI‹0.9 increased by 10 times the risk of advanced subclinical atherogenesis (CIMT ›0.05cm). This suggests the value of ABI as a non-invasive marker of subclinical atherogenesis and possibly also for cardiovascular events in patients with CLD.

REFERENCES

1. Boletín de Estadística de Mortalidad en México, Dirección General de Información en Salud, de la Secretaria de Salud, 2003.

2. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. J Am Med Assoc 2008;299:2777-88.

3. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189e97.

4. Kakami M, Koda M, Murawaki Y. The prevalence of atherosclerosis in cirrhotic patients: assessment of two aspects of atherosis and sclerosis. Hepatol Res 2007;37:152-157.

5. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrosis. J Hepatol 2007;46:927-934.

6. Mohammadi A, Habibpour H, Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011;7:661-665.

7. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197-208.

8. Guo X, Li J, Pang W, Zhao M, Luo Y, Sun Y, et al. Sensitivity and specificity of ankle-brachial index for detecting angiographic stenosis of peripheral arteries. Circ J 2008;72:605-10.

9. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993;88(3):837-45.

10. Targher G. et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007;46:1126-1132.

11. Smith FB, Lee AJ, Price JF, van Wijk MCW, Fowkes FGR. Changes in ankle brachial index in symptomatic and asymptomatic subjects in the general population. J Vasc Surg 2003;38:1323-30.

12. Trujillo-Alcocer JC, Flores-Escartin MH, Lópes-Monterrubio AR, Serrano-Lozano JA. Prevalencia de enfermedad arterial periférica. Rev Mex Angiol 2014;42(2): 62-67.

13. Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109.

14. Kozanova M, Palombo C, Eng MP, Decker J, et al. Fatty liver index gamma-glutamyltransferase, and early carotid plaques. Hepatol 2012;55:1406-15.

15. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, et al. CARMELA Study Investigators. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008;121:58-65.

16. Feig DI, Kang DH and Johnson RJ. Uric Acid and Cardiovascular Risk. N Engl J Med 2008;359(17):1811-21.

17. Cebollada J, Gimenob JA. Ácido úrico como factor de riesgo cardiovascular. Hipertens Riesgo Vasc 2012;29(2):36-43.